Preoperative biomarker panel distinguishes PDAC from IPMN

Objectives Pancreatic ductal adenocarcinoma (PDAC) is associated with increased coagulation and venous thrombotic events (VTE). PDAC is often diagnosed late and survival is poor. CA 19-9 is the most used tumor marker for PDAC, but it is more useful in follow-up than diagnosis. Intraductal papillary mucinous neoplasm (IPMN) is a benign tumor of the pancreas, which can become malignant, however pancreatic tumor surgery is extensive and should not be done needlessly. The aim of this study was to study whether PDAC could be distinguished from IPMN preoperatively using coagulation biomarkers and whether combing them in a panel score aids diagnostics.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Nora Mattila, Hanna Sepp änen, Caj Haglund, Harri Mustonen, Beata Przybyla, Riitta Lassila Tags: 8. Pancreatic Cancer I Source Type: research